BioRestorative Therapies Inc (BRTX) - Net Assets
Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) has net assets worth $3.03 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.64 Million) and total liabilities ($1.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of BioRestorative Therapies Inc for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.03 Million |
| % of Total Assets | 65.2% |
| Annual Growth Rate | -17.32% |
| 5-Year Change | -98.35% |
| 10-Year Change | N/A |
| Growth Volatility | 42.52 |
BioRestorative Therapies Inc - Net Assets Trend (2009–2025)
This chart illustrates how BioRestorative Therapies Inc's net assets have evolved over time, based on quarterly financial data. Check BRTX tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for BioRestorative Therapies Inc (2009–2025)
The table below shows the annual net assets of BioRestorative Therapies Inc from 2009 to 2025. For live valuation and market cap data, see how much is BioRestorative Therapies Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $356.74K | -95.82% |
| 2024-12-31 | $8.53 Million | -14.72% |
| 2023-12-31 | $10.00 Million | -2.78% |
| 2022-12-31 | $10.29 Million | -52.35% |
| 2021-12-31 | $21.60 Million | +1722.01% |
| 2020-12-31 | $-1.33 Million | +89.58% |
| 2019-12-31 | $-12.78 Million | -47.85% |
| 2018-12-31 | $-8.64 Million | -26.39% |
| 2017-12-31 | $-6.84 Million | -36.72% |
| 2016-12-31 | $-5.00 Million | -27.93% |
| 2015-12-31 | $-3.91 Million | +43.26% |
| 2014-12-31 | $-6.89 Million | -3.04% |
| 2013-12-31 | $-6.69 Million | -30.02% |
| 2012-12-31 | $-5.14 Million | -39.48% |
| 2011-12-31 | $-3.69 Million | -395.34% |
| 2010-12-31 | $-744.22K | -109.95% |
| 2009-12-31 | $7.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioRestorative Therapies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16992069000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $887.00 | 0.25% |
| Other Components | $170.28 Million | 47730.74% |
| Total Equity | $356.74K | 100.00% |
BioRestorative Therapies Inc Competitors by Market Cap
The table below lists competitors of BioRestorative Therapies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sonoro Energy Ltd
V:SNV
|
$5.22 Million |
|
CASA DE BUCOVINA-CLUB DE MUNTE
RO:BCM
|
$5.22 Million |
|
Signature Resources Ltd
V:SGU
|
$5.22 Million |
|
Tatton Asset Management plc
LSE:TAM
|
$5.23 Million |
|
JPMorgan UK Small Cap Growth & Income Plc
LSE:JUGI
|
$5.21 Million |
|
Organoclick AB
ST:ORGC
|
$5.21 Million |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
$5.21 Million |
|
Inca Minerals Ltd
AU:ICG
|
$5.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioRestorative Therapies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,531,393 to 356,744, a change of -8,174,649 (-95.8%).
- Net loss of 14,241,975 reduced equity.
- Dividend payments of 270,573 reduced retained earnings.
- New share issuances of 3,096,250 increased equity.
- Other factors increased equity by 3,241,649.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.24 Million | -3992.21% |
| Dividends Paid | $270.57K | -75.85% |
| Share Issuances | $3.10 Million | +867.92% |
| Other Changes | $3.24 Million | +908.68% |
| Total Change | $- | -95.82% |
Book Value vs Market Value Analysis
This analysis compares BioRestorative Therapies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $-695.53 | $0.20 | x |
| 2011-12-31 | $-24413.23 | $0.20 | x |
| 2012-12-31 | $-27643.51 | $0.20 | x |
| 2013-12-31 | $-28088.53 | $0.20 | x |
| 2014-12-31 | $-16246.21 | $0.20 | x |
| 2015-12-31 | $-4726.07 | $0.20 | x |
| 2016-12-31 | $-4259.18 | $0.20 | x |
| 2017-12-31 | $-4474.19 | $0.20 | x |
| 2018-12-31 | $-2947.15 | $0.20 | x |
| 2019-12-31 | $-656.47 | $0.20 | x |
| 2020-12-31 | $-3.37 | $0.20 | x |
| 2021-12-31 | $18.18 | $0.20 | x |
| 2022-12-31 | $2.84 | $0.20 | x |
| 2023-12-31 | $2.37 | $0.20 | x |
| 2024-12-31 | $1.10 | $0.20 | x |
| 2025-12-31 | $0.04 | $0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioRestorative Therapies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3992.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3959.40%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 11.44x
- Recent ROE (-3992.21%) is below the historical average (-283.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.19 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.71 Million |
| 2012 | 0.00% | -41931.63% | 0.01x | 0.00x | $-6.02 Million |
| 2013 | 0.00% | -342332.98% | 0.00x | 0.00x | $-5.08 Million |
| 2014 | 0.00% | -1343.19% | 0.25x | 0.00x | $-4.90 Million |
| 2015 | 0.00% | -1259.87% | 0.31x | 0.00x | $-7.53 Million |
| 2016 | 0.00% | -23755.44% | 0.02x | 0.00x | $-8.14 Million |
| 2017 | 0.00% | -11660.07% | 0.05x | 0.00x | $-8.76 Million |
| 2018 | 0.00% | -11277.30% | 0.09x | 0.00x | $-11.65 Million |
| 2019 | 0.00% | -11267.61% | 0.09x | 0.00x | $-13.37 Million |
| 2020 | 0.00% | -14639.85% | 0.02x | 0.00x | $-11.14 Million |
| 2021 | -205.14% | -96311.51% | 0.00x | 1.04x | $-46.46 Million |
| 2022 | -128.49% | -11036.97% | 0.01x | 1.60x | $-14.25 Million |
| 2023 | -104.13% | -7145.20% | 0.01x | 1.26x | $-11.42 Million |
| 2024 | -105.25% | -2239.25% | 0.03x | 1.44x | $-9.83 Million |
| 2025 | -3992.21% | -3959.40% | 0.09x | 11.44x | $-14.28 Million |
Industry Comparison
This section compares BioRestorative Therapies Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioRestorative Therapies Inc (BRTX) | $3.03 Million | 0.00% | 0.53x | $5.22 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more